Generation of B lymphoma cell lines from knockout mice by transformation in vivo with an Emu-myc transgene.

J Immunol Methods

Immunology Division, The Walter and Eliza Hall Institute of Medical Research, PO Royal Melbourne Hospital, Melbourne, Australia.

Published: August 1999

While a great deal has been learned about the genetic control of B lymphocyte behavior through the observation of primary B cells from mice bearing targeted gene mutations, such studies can be restricted by the limited number and longevity of the cells ex vivo, by their heterogeneity, and by the inability to apply further genetic manipulations. Here we describe a protocol for the efficient derivation of mutant B lymphoma cell lines, by crossing mice bearing targeted mutations in genes affecting mature B cell function with transgenic mice bearing the lymphomagenic Emu-myc transgene. Pre-B and B lymphomas were obtained with high frequency, and the cells were readily adaptable to culture. The B lymphoma lines bore surface markers consistent with an immature phenotype and were amenable to cloning and to stable transfection. They are currently being used as a well-defined and unlimited cell source to study antigen receptor signalling and B cell-specific gene regulation, and the dependence of these processes on the products of the vav, CD45, lyn, oct-2, btk and OBF-1 genes.

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0022-1759(99)00094-0DOI Listing

Publication Analysis

Top Keywords

mice bearing
12
lymphoma cell
8
cell lines
8
emu-myc transgene
8
bearing targeted
8
generation lymphoma
4
cell
4
lines knockout
4
mice
4
knockout mice
4

Similar Publications

Self-transmissible IncC plasmids rapidly spread multidrug resistance in many medically important pathogens worldwide. A large plasmid of this type (pIP1202, ~80 Kb) has been isolated in a clinical isolate of , the agent of plague. Here, we report that pIP1202 was highly stable in infected mice and fleas and did not reduce virulence in these animals.

View Article and Find Full Text PDF

Monomethyl auristatin E (MMAE) is a promising treatment option for patients diagnosed with prostate cancer (PCa); however, toxicities prevent MMAE from being administered as free drug. No MMAE-based treatment is currently marketed for PCa. Herein, we describe a small-molecule-drug conjugate, CTT2274, for the selective delivery of MMAE.

View Article and Find Full Text PDF

Both photothermal therapy (PTT) and chemodynamic therapy (CDT) are designed to focus their antitumor effect on only the tumor site, thereby minimizing unwanted severe damage to healthy tissue outside the tumor. However, each monotherapy is limited in achieving complete tumor eradication, resulting in tumor recurrence. The combination of multiple therapies may help to overcome the limitations of single therapy, improve the chances of complete tumor eradication, and reduce the risk of recurrence.

View Article and Find Full Text PDF

PDE4 inhibitor rolipram represses hedgehog signaling via ubiquitin-mediated proteolysis of GLI transcription factors to regress breast cancer.

J Biol Chem

January 2025

Cell and Molecular Biology Laboratory, Department of Zoology, University of Kalyani, Kalyani, Nadia, West Bengal, India, 741235. Electronic address:

Aberrant activation of the hedgehog (Hh) signaling pathway positively correlates with progression, invasion and metastasis of several cancers, including breast cancer. Although numerous inhibitors of the Hh signaling pathway are available, several oncogenic mutations of key components of the pathway, including Smoothened (Smo), have limited their capability to be developed as putative anti-cancer drugs. In this study, we have modulated the Hh signaling pathway in breast cancer using a specific FDA-approved phosphodiesterase 4 (PDE4) inhibitor rolipram.

View Article and Find Full Text PDF

Development of Chimeric Nanobody-Granzyme B Functionalized Ferritin Nanoparticles for Precise Tumor Therapy.

Pharmacol Res

January 2025

Medical Research Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, 510080, China. Electronic address:

T-cell lymphomas (TCLs) are heterogeneous malignancies with limited treatment options and poor outcomes. The efficacy of traditional T-cell therapies, including chimeric antigen receptor (CAR) T cells, is often constrained by immunosuppressive factors and the tumor microenvironment. On the other hand, although direct Granzyme B (GrB) administration can effectively induce tumor cell apoptosis, it lacks universal tumor targeting and efficient cellular entry mechanisms.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!